A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-C3 in Adult Healthy Volunteers and in Adult Patients With Complement-Mediated Renal Disease

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506690-36-00

Acronym

AROC3-1001

Enrollment

Registered

2023-12-07

Start date

2024-05-06

Completion date

Unknown

Last updated

2025-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

complement-mediated renal disease

Brief summary

Incidence, frequency, and severity of treatment-emergent adverse events (TEAEs)

Detailed description

Plasma PK of ARO-C3, Changes and percent change from baseline in serum complement component (C) 3 (C3) at scheduled visits

Interventions

DRUGARO-C3

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence, frequency, and severity of treatment-emergent adverse events (TEAEs)	—

Secondary

Measure	Time frame
Plasma PK of ARO-C3, Changes and percent change from baseline in serum complement component (C) 3 (C3) at scheduled visits	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026